Moreover, overexpression of TIM-3/Gal-9 has been found in AML patients who failed chemotherapy, suggesting that targeting TIM-3/Gal-9 in combination with chemotherapy induction may be an alternative approach to increasing the complete remission rate of patients with AML (52, 82). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.